This early research tested a new medication named TOP-N53 in a small group of 29 healthy men. The team gave each participant a single dose under the skin and watched them for up to 24 hours. They measured safety, how the drug moved through the body, and changes in skin blood flow using a special imaging tool called Laser Speckle Contrast Imaging.
The main finding was that the drug caused a sustained increase in local skin blood flow. This effect grew stronger with higher doses, specifically at 4.84 micrograms and 9.075 micrograms. No serious side effects occurred, and the drug was considered safe and well tolerated by the volunteers during this short observation period.
While these results are encouraging for future development of a topical treatment for chronic wounds, readers should be careful not to assume this drug is ready for use. This was a Phase I trial focused on safety in healthy people, not patients with wounds. More research is needed to confirm if it helps heal wounds in sick patients.